Subscribe to Search results

The annual return taken from Glasgow in 1976, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1977, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1978, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1979 saw a reduction in the use of cryoprecipitate and an increase in the use of concentrates, both NHS and (in particular) commercial

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes stated that the majority of discussions taking place around 1975 were centred around the types of donors used to give plasma in commercial centres.

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes held that the risk of dying due to a bleed outweighed the possible downside of using factor concentrates.

Published on:

Dr Forbes agrees with a letter written by Dr John Cash on 24 January 1976, with held that that the importation of Factor VIII concentrates was "bringing with it a potentially lethal virus into the whole community" in reference to hepatitis.

Published on:

During 1978, before the complications had become apparent, Dr Forbes described the recent move to home treatment as highly valuable for patients.

Published on:

By 1976 Factor 9 concentrate was the dominant treatment with comparatively little use of fresh frozen plasma. The 1976 annual returns recorded that 396 patients were treated with a total of 5,561,834 Factor 9 units in the UK. The average per patient was 18,790 units. 60 patients were on home treatment.

Published on:

In 1978, the average amount used per patient was 21,000 units, which was an increase from 1976, but said to be a decrease from 1977 when the annual figure was 23,000 units

Published on:

There was an increase of fresh frozen plasma in 1980 both of the overall amount used and the average per patient. The average used per Haemophilia B patient was now 23,301 units.

Published on:

Information received from haemophilia centres' annual returns shows the average amount of NHS Factor 9 used per Haemophilia B patient that year was 21,000 units.

Published on:

Information received from haemophilia centres' annual returns shows the average amount of NHS Factor 9 used per Haemophilia B patient that year was 25,005 units.

Published on:

Dr Craske prepared a report titled Current Situation Regarding AIDS, attaching diagrams based on the reports received from haemophilia centres on the patients who received the same batches of blood products as the Cardiff and Bristol AIDS cases.

Published on:

Information received from haemophilia centres' annual returns shows the average amount of NHS Factor 9 used per Haemophilia B patient that year was 29,241 units.

Published on:

Information received from haemophilia centres' annual returns shows the average amount of NHS Factor 9 used per Haemophilia B patient that year was 30,752 units.

Published on:

Information received from haemophilia centres' annual returns shows the average amount of NHS Factor 9 used per Haemophilia B patient that year was 27,487 units.

Published on:

In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske described the supply of Factor 9 to Haemophilia B patients as "always more than adequate".

Published on:

In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske described Haemophilia B patients as "a high risk group for hepatitis".

Published on:

In a report prepared for the Scottish Health Service Haemophilia Centre/Transfusion Service Directors' meeting, Dr Craske reported that Supernine was at an advanced stage of development.

Published on: